Together, these results suggest that the combination of SHP2 inhibition and inhibition of downstream MAPK pathways, such as cell cycle regulators, is a promising strategy for treatment of KRAS-driven cancers regardless of KRAS genotype. Here, PTPN11 is linked to cancer.